Clinical research - Press Releases

Date	Title	Company
20-Nov-2023	Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment	Landmark medicines
20-Nov-2023	Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis	Chiesi Group
20-Nov-2023	Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6	Omnix Medical
17-Nov-2023	CluePoints wins SCRIP Awards for Best Contract Research Organization (CRO): Specialist Providers	CluePoints
17-Nov-2023	Symbio & Dow Group Merges with Proinnovera to Form Leading Dermatology CRO, Symbio Proinnovera	Symbio & Dow Group / Proinnovera
16-Nov-2023	Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer	Curium
16-Nov-2023	Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence	Versameb AG
16-Nov-2023	Cell and Gene Therapy Catapult focuses on strategic areas to further unlock the full potential of the UK advanced therapy industry	The Cell and Gene Therapy Catapult
16-Nov-2023	POLB 001 LPS Challenge Trial Data to be Presented at IUIS	Poolbeg Pharma plc
16-Nov-2023	Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma	Certa Therapeutics
15-Nov-2023	SMART researchers pioneer novel microfluidic method to optimise bone marrow stem cell extraction for advanced cell therapies	Singapore-MIT Alliance for Research and Technology (SMART)
14-Nov-2023	Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria	Glox Therapeutics
14-Nov-2023	Post hoc analysis showed meaningful efficacy of certolizumab pegol for RA patients with high Rheumatoid Factor (RF) levels	UCB
14-Nov-2023	FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer	FluoGuide
14-Nov-2023	Oncopeptides Chief Financial Officer Henrik Bergentoft takes office today	Oncopeptides
14-Nov-2023	Tune Therapeutics Reveals Epigenetic Editing Program Targeting Hepatitis B Virus	Tune Therapeutics
14-Nov-2023	Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases	Almirall
14-Nov-2023	Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round	Nouscom
14-Nov-2023	The Revolutionary Era of Liquid Biopsy: A Non-Invasive Approach to Precision Medicine	Roots Analysis
13-Nov-2023	Bloomsbury Genetic Therapies Celebrates its One Year Anniversary and Outlines Key Strategic and Operational Achievements since Launch	Bloomsbury Genetic Therapies